Phase II SORAML Trial of Sorafenib versus Placebo in Addition to Standard Therapy for Younger Patients with Newly Diagnosed AML


Phase II SORAML Trial of Sorafenib versus Placebo in Addition to Standard Therapy for Younger Patients with Newly Diagnosed AML
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Mikkael A Sekeres, MD, MS (1/20/15)
Rollig C et al. Sorafenib versus placebo in addition to standard therapy in younger patients with newly diagnosed acute myeloid leukemia: Results from 267 patients treated in the randomized placebo-controlled SAL-SORAML trial. Proc ASH 2014;Abstract 6.

Dr Sekeres is Professor of Medicine and Director of the Leukemia Program at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio.